Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus polymerase antigen refers to the multifunctional enzyme encoded by the Hepatitis B virus (HBV) that is essential for viral replication. This protein, often called HBV polymerase or P protein, is a major target for antiviral therapies and plays several critical roles in the HBV life cycle. It consists of four main domains: Terminal Protein (TP), Spacer, Reverse Transcriptase (RT), and RNase H. The primary functions include reverse transcription, RNA binding/packaging, and RNase H degradation. It also inhibits host innate immunity, interfering with interferon signaling. All current direct antiviral drugs targeting hepatitis B act on this enzyme—specifically inhibiting its reverse transcriptase activity.
Inhibition of reverse transcriptase activity
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus polymerase antigen (HBV Polymerase).